| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| GIV-IN PV Trial | 24-99 | JAK2V617F-positive high-risk Polycythemia Vera patients |
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high-risk polycythemia vera patients. |
DSSG Group: Lymphoma & blood cancers
BD – Bone Marrow/Blood
| Name | No. | For Patients with | Purpose | |
|---|---|---|---|---|
| BD – Bone Marrow/Blood | Healthy Volunteers for Research and Development Purpose |
|
LOXO-BTK-20022
| Name | No. | For Patients with | Purpose | |
|---|---|---|---|---|
| LOXO-BTK-20022 | 21-44 | Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
Discontinuation Study
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Discontinuation Study | 20-28 | Multiple Myeloma |
To assess how many patients remain in remission after 12 months of stopping maintenance therapy |
MRD Study
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MRD Study | 21-23 | Patients with Myeloma. |
Minimal residual disease (MRD). This is a test performed on the patients DNA at diagnosis by Next Generation Sequencing (NGS), which can detect if there are trace amounts of the cancer remaining in a patient after treatment, and has been shown to be highly predictive of long-term outcomes in several studies. |
MK-1026-003
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK-1026-003 | 21-22 | Hematologic malignancies of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM) |
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM). |
BRUIN CLL-322
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| BRUIN CLL-322 | 20-21-44 | Previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma |
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years. |